MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS

被引：0
|
作者：
Wild, L. [1 ]
Forster, L. [1 ]
机构：
[1] Double Helix Consulting, London, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.566
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A335 / A336
页数：2
相关论文
共 50 条
  • [41] The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
    Wasir, Riswandy
    Irawati, Sylvi
    Makady, Amr
    Postma, Maarten
    Goettsch, Wim
    Feenstra, Talitha
    Buskens, Erik
    PLOS ONE, 2019, 14 (11):
  • [42] EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
    Badia, F. J.
    Poveda, J. L.
    Tort, M.
    Tania, V
    Shepherd, J.
    VALUE IN HEALTH, 2019, 22 : S855 - S855
  • [43] Indication-based pricing of the pharmaceuticals in Croatia: case-study
    Bobinac, Ana
    Voncina, Luka
    Velic, Ismar
    Ribaric, Elizabeta
    Benkovic, Vanesa
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [44] DETERMINING THE EXPECTED PRICING ADVANTAGE OF FIRST-IN-INDICATION AND FIRST-IN-CLASS NON-ONCOLOGY ORPHAN PRODUCTS
    Donnelly, E.
    Privett, B.
    Krieger, D.
    VALUE IN HEALTH, 2024, 27 (06) : S62 - S62
  • [45] SOCIETAL PREFERENCES FOR FUNDING ORPHAN DRUGS IN THE UK: AN APPLICATION OF VALUE BASED PRICING USING DISCRETE CHOICE EXPERIMENT METHODS
    Bourke, S. M.
    Plumpton, C. O.
    Hughes, D. A.
    VALUE IN HEALTH, 2017, 20 (09) : A559 - A559
  • [46] Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations
    Ulf Persson
    J. M. Norlin
    Applied Health Economics and Health Policy, 2018, 16 : 157 - 165
  • [47] Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations
    Persson, Ulf
    Norlin, J. M.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (02) : 157 - 165
  • [48] From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy (vol 8, pg 251, 2024)
    Rossini, Elvio Emanuele
    Galeone, Carlotta
    Lucchetti, Chiara
    Jommi, Claudio
    PHARMACOECONOMICS-OPEN, 2024,
  • [49] Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe
    Vokinger, Kerstin N.
    Kesselheim, Aaron S.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (01) : 1 - 2
  • [50] ADEQUATE DATA SOURCES TO FACILITATE INNOVATIVE PRICING SOLUTIONS FOR PHARMACEUTICALS WITH MULTIPLE INDICATIONS IN GERMANY
    Vogelmann, T.
    Ikenberg, R.
    Stiefel, J.
    VALUE IN HEALTH, 2019, 22 : S492 - S492
12345